Skip to main content

Advertisement

SpringerLink
Log in

Laboratory biomarkers in Alzheimer’s disease

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Diagnosis and monitoring of Alzheimer’s disease and the related dementias have long depended principally on clinical examination, especially cognitive testing. Establishment of biomarkers, which might assist in diagnosis or tracking of disease progression, would be a highly valuable addition to the care of patients. Such biomarkers are potentially available from body fluids and tissues as well as from brain imaging data. As specific disease-modifying therapies for Alzheimer’s disease are developed, biomarkers may improve diagnostic accuracy and facilitate clinical trials, allowing a better gauge of treatment response. In this review, we focus on biomarkers in cerebrospinal fluid and plasma, including measurements of the proteins tau and beta-amyloid.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Thal LJ, Kantarci K, Reiman EM, et al.: The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 2006, 20:6–15.

    Article  PubMed  Google Scholar 

  2. Mayeux R: Biomarkers: potential uses and limitations. NeuroRx 2004, 1:182–188.

    Article  PubMed  Google Scholar 

  3. Cummings JL: Clinical evaluation as a biomarker for Alzheimer’s disease. J Alzheimers Dis 2005, 8:327–337.

    PubMed  CAS  Google Scholar 

  4. Frank RA, Galasko D, Hampel H, et al.: Biological markers for therapeutic trials in Alzheimer’s disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer’s disease. Neurobiol Aging 2003, 24:521–536.

    Article  PubMed  Google Scholar 

  5. Dickerson BC, Sperling RA: Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer’s disease. NeuroRx 2005, 2:348–360.

    Article  PubMed  Google Scholar 

  6. Consensus report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease.“ The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Neurobiol Aging 1998, 19:109–116.

    Article  Google Scholar 

  7. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002, 297:353–356.

    Article  PubMed  CAS  Google Scholar 

  8. Galasko D, Chang L, Motter R, et al.: High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998, 55:937–945.

    Article  PubMed  CAS  Google Scholar 

  9. Mehta PD, Pirttila T, Mehta SP, et al.: Plasma and cerebrospinal fluid levels of amyloid beta proteins 1–40 and 1–42 in Alzheimer disease. Arch Neurol 2000, 57:100–105.

    Article  PubMed  CAS  Google Scholar 

  10. Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K: Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J Proteome Res 2006, 5:1010–1016.

    Article  PubMed  CAS  Google Scholar 

  11. Sunderland T, Linker G, Mirza N, et al.: Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003, 289:2094–2103.

    Article  PubMed  Google Scholar 

  12. Blennow K: Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx 2004, 1:213–225.

    Article  PubMed  Google Scholar 

  13. Peskind ER, Li G, Shofer J, et al.: Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol 2006, 63:936–939.

    Article  PubMed  Google Scholar 

  14. Sunderland T, Mirza N, Putnam KT, et al.: Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer’s disease: the effect of APOE epsilon4 allele. Biol Psychiatry 2004, 56:670–676.

    Article  PubMed  CAS  Google Scholar 

  15. Riemenschneider M, Schmolke M, Lautenschlager N, et al.: Cerebrospinal beta-amyloid ((1–42)) in early Alzheimer’s disease: association with apolipoprotein E genotype and cognitive decline. Neurosci Lett 2000, 284:85–88.

    Article  PubMed  CAS  Google Scholar 

  16. de Leon MJ, DeSanti S, Zinkowski R, et al.: Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 2006, 27:394–401.

    Article  PubMed  Google Scholar 

  17. Andreasen N, Hesse C, Davidsson P, et al.: Cerebrospinal fluid beta-amyloid(1–42) in Alzheimer disease: differences between early-and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999, 56:673–680.

    Article  PubMed  CAS  Google Scholar 

  18. Tapiola T, Pirttila T, Mikkonen M, et al.: Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer’s disease. Neurosci Lett 2000, 280:119–122.

    Article  PubMed  CAS  Google Scholar 

  19. Strozyk D, Blennow K, White LR, Launer LJ: CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003, 60:652–656.

    PubMed  CAS  Google Scholar 

  20. Fagan AM, Mintun MA, Mach RH, et al.: Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006, 59:512–519.

    Article  PubMed  CAS  Google Scholar 

  21. Georganopoulou DG, Chang L, Nam JM, et al.: Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease. Proc Natl Acad Sci U S A 2005, 102:2273–2276.

    Article  PubMed  CAS  Google Scholar 

  22. Portelius E, Zetterberg H, Andreasson U, et al.: An Alzheimer’s disease-specific beta-amyloid fragment signature in cerebrospinal fluid. Neurosci Lett 2006, 409:215–219.

    Article  PubMed  CAS  Google Scholar 

  23. Bateman RJ, Wen G, Morris JC, Holtzman DM: Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 2007, 68:666–669.

    Article  PubMed  CAS  Google Scholar 

  24. Mehta PD, Pirttila T, Patrick BA, et al.: Amyloid beta protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett 2001, 304:102–106.

    Article  PubMed  CAS  Google Scholar 

  25. Mayeux R, Honig LS, Tang MX, et al.: Plasma A[beta]40 and A[beta]42 and Alzheimer’s disease: relation to age, mortality, and risk. Neurology 2003, 61:1185–1190.

    PubMed  CAS  Google Scholar 

  26. van Oijen M, Hofman A, Soares HD, et al.: Plasma Abeta(1–40) and Abeta(1–42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 2006, 5:655–660.

    Article  PubMed  Google Scholar 

  27. Graff-Radford NR, Crook JE, Lucas J, et al.: Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007, 64:354–362.

    Article  PubMed  Google Scholar 

  28. Hyman BT, Smith C, Buldyrev I, et al.: Autoantibodies to amyloid-beta and Alzheimer’s disease. Ann Neurol 2001, 49:808–810.

    Article  PubMed  CAS  Google Scholar 

  29. Hampel H, Buerger K, Zinkowski R, et al.: Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry 2004, 61:95–102.

    Article  PubMed  CAS  Google Scholar 

  30. Hesse C, Rosengren L, Andreasen N, et al.: Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 2001, 297:187–190.

    Article  PubMed  CAS  Google Scholar 

  31. Buerger K, Otto M, Teipel SJ, et al.: Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. Neurobiol Aging 2006, 27:10–15.

    Article  PubMed  CAS  Google Scholar 

  32. Buerger K, Ewers M, Pirttila T, et al.: CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain 2006, 129:3035–3041.

    Article  PubMed  Google Scholar 

  33. Itoh N, Arai H, Urakami K, et al.: Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer’s disease. Ann Neurol 2001, 50:150–156.

    Article  PubMed  CAS  Google Scholar 

  34. Maddalena A, Papassotiropoulos A, Muller-Tillmanns B, et al.: Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. Arch Neurol 2003, 60:1202–1206.

    Article  PubMed  Google Scholar 

  35. Andreasen N, Minthon L, Davidsson P, et al.: Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001, 58:373–379.

    Article  PubMed  CAS  Google Scholar 

  36. Gomez-Tortosa E, Gonzalo I, Fanjul S, et al.: Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Arch Neurol 2003, 60:1218–1222.

    Article  PubMed  Google Scholar 

  37. Clark CM, Xie S, Chittams J, et al.: Cerebrospinal fluid tau and beta-amyloid: How well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 2003, 60:1696–1702.

    Article  PubMed  Google Scholar 

  38. Buerger K, Zinkowski R, Teipel SJ, et al.: Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 2002, 59:1267–1272.

    Article  PubMed  Google Scholar 

  39. Schoonenboom NS, Pijnenburg YA, Mulder C, et al.: Amyloid beta(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 2004, 62:1580–1584.

    PubMed  CAS  Google Scholar 

  40. Riemenschneider M, Lautenschlager N, Wagenpfeil S, et al.: Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 2002, 59:1729–1734.

    Article  PubMed  CAS  Google Scholar 

  41. Hampel H, Teipel SJ, Fuchsberger T, et al.: Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer’s disease in patients with mild cognitive impairment. Mol Psychiatry 2004, 9:705–710.

    PubMed  CAS  Google Scholar 

  42. Sun YX, Minthon L, Wallmark A, et al.: Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 2003, 16:136–144.

    Article  PubMed  CAS  Google Scholar 

  43. Hansson O, Zetterberg H, Buchhave P, et al.: Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006, 5:228–234.

    Article  PubMed  CAS  Google Scholar 

  44. Herukka SK, Hallikainen M, Soininen H, Pirttila T: CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 2005, 64:1294–1297.

    PubMed  CAS  Google Scholar 

  45. Fagan AM, Roe CM, Xiong C, et al.: Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007, 64:343–349.

    Article  PubMed  Google Scholar 

  46. Pratico D, Clark CM, Liun F, et al.: Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol 2002, 59:972–976.

    Article  PubMed  Google Scholar 

  47. Han X, Fagan AM, Cheng H, et al.: Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann Neurol 2003, 54:115–119.

    Article  PubMed  CAS  Google Scholar 

  48. de la Monte SM, Wands JR: The AD7c-ntp neuronal thread protein biomarker for detecting Alzheimer’s disease. Front Biosci 2002, 7:d989–996.

    Article  PubMed  Google Scholar 

  49. Finehout EJ, Franck Z, Choe LH, et al.: Cerebrospinal fluid proteomic biomarkers for Alzheimer’s disease. Ann Neurol 2007, 61:120–129.

    Article  PubMed  CAS  Google Scholar 

  50. Devanand DP, Pradhaban G, Liu X, et al.: Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 2007, 68:828–836.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Gertrude H. Sergievsky Center, and The Neurological Institute and Department of Neurology, Columbia University College of Physicians & Surgeons, P&S Box 16, 630 West 168th Street, New York, NY, 10032, USA

    Lawrence S. Honig

Authors
  1. Joshua R. Steinerman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lawrence S. Honig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lawrence S. Honig.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steinerman, J.R., Honig, L.S. Laboratory biomarkers in Alzheimer’s disease. Curr Neurol Neurosci Rep 7, 381–387 (2007). https://doi.org/10.1007/s11910-007-0059-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-007-0059-6

Keywords

Search

Navigation